View Item 

Show simple item record

Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy

dc.contributor.authorTsung, Irene
dc.contributor.authorDolan, Russell
dc.contributor.authorLao, Christopher D.
dc.contributor.authorFecher, Leslie
dc.contributor.authorRiggenbach, Kane
dc.contributor.authorYeboah‐korang, Amoah
dc.contributor.authorFontana, Robert J.
dc.date.accessioned2019-10-30T15:31:41Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2019-10-30T15:31:41Z
dc.date.issued2019-10
dc.identifier.citationTsung, Irene; Dolan, Russell; Lao, Christopher D.; Fecher, Leslie; Riggenbach, Kane; Yeboah‐korang, Amoah ; Fontana, Robert J. (2019). "Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy." Alimentary Pharmacology & Therapeutics 50(7): 800-808.
dc.identifier.issn0269-2813
dc.identifier.issn1365-2036
dc.identifier.urihttps://hdl.handle.net/2027.42/151912
dc.publisherWiley Periodicals, Inc.
dc.titleLiver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOtolaryngology
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/151912/1/apt15413-sup-0001-FigS1.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/151912/2/apt15413.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/151912/3/apt15413_am.pdf
dc.identifier.doi10.1111/apt.15413
dc.identifier.sourceAlimentary Pharmacology & Therapeutics
dc.identifier.citedreferenceWang W, Lie P, Guo M, He J. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and metaâ analysis of published data. Int J Cancer. 2017; 141: 1018 â 1028.
dc.identifier.citedreferenceFontana RJ, Watkins PB, Bonkovsky HL, et al. Drug induced liver injury network prospective study. Drug Saf. 2009; 32: 55 â 68.
dc.identifier.citedreferencePostow MA, Sidlow R, Hellmann MD. Immuneâ related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018; 378: 158 â 168.
dc.identifier.citedreferenceHaanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and followâ up. Ann Oncol. 2017; 28 ( suppl_4 ): iv119 â iv142.
dc.identifier.citedreferenceChuk MK, Chang JT, Theoret MR, et al. FDA approval summary: accelerated approval of pembrolizumab for secondâ line treatment of metastatic melanoma. Clin Cancer Res. 2017; 23: 5666 â 5670.
dc.identifier.citedreferenceWang Pâ F, Chen Y, Song Sâ Y, et al. Immuneâ related adverse events associated with antiâ PDâ 1/ PDâ L1 treatment for malignancies: a metaâ analysis. Front Pharmacol. 2017; 8: 730 â 740.
dc.identifier.citedreferenceJohncilla M, Misdraji J, Pratt DS, et al. Ipilimumabâ associated hepatitis: clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol. 2015; 39: 1075 â 1084.
dc.identifier.citedreferenceRockey DC, Seeff LB, Rochon J, et al. Causality assessment in drugâ induced liver injury using a structured expert opinion process: comparison to the Rousselâ Uclaf Assessment method. Hepatology. 2010; 51: 2117 â 2126.
dc.identifier.citedreferenceZen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug induced liver injury. Mod Pathol. 2017; 31: 965 â 973.
dc.identifier.citedreferenceDeMartin E, Michot JM, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatology. 2018; 68: 81 â 90.
dc.identifier.citedreferenceKleiner DE, Berman D. Pathologic changes in Ipilimumabâ related hepatitis in patients with metastatic melanoma. Dig Dis Sci. 2012; 57: 2233 â 2240.
dc.identifier.citedreferenceFriedman CF, Proverbsâ Singh TA, Postow MA. Treatment of the immuneâ related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016; 2: 1346 â 1353.
dc.identifier.citedreferenceHuffman BM, Kottschade LA, Kamath PS, Markovic SN. Hepatotoxicity after Immune Checkpoint inhibitor therapy in Melanoma. Natural progression and Management. Am J Clin Oncol. 2017; 41: 760 â 765.
dc.identifier.citedreferenceBrahmer J, Lacchetti C, Schneider BJ, et al. Management of immuneâ related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Practice Guideline. J Clin Oncol. 2018; 36: 1714 â 1768.
dc.identifier.citedreferenceBenichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugsâ II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clinical Epidemiology. 1993; 46: 1331 â 1336.
dc.identifier.citedreferenceBeaver JA, Howie LJ, Pelosof L, et al. A 25â year experience of US Food and drug administration accelerated approval of malignant hematology and oncology drugs and biologics: a review. JAMA Oncol. 2018; 4: 849 â 856.
dc.identifier.citedreferenceSuzman DL, Pelosof L, Rosenberg A, Avigan MI. Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents. Liver Int. 2018; 38: 976 â 987.
dc.identifier.citedreferenceSharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015; 348: 7.
dc.identifier.citedreferenceLeach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLAâ 4 blockade. Science. 1996; 271: 1734 â 1736.
dc.identifier.citedreferenceSharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011; 11: 805 â 812.
dc.identifier.citedreferenceHassel JC, Heinzerling L, Aberle J, et al. Combined immune checkpoint blockade (antiâ PDâ 1/antiâ CTLAâ 4): evaluation and management of adverse drug reactions. Cancer Treat Rev. 2017; 57: 36 â 49.
dc.identifier.citedreferenceWang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and metaâ analysis. JAMA Oncol. 2018; 4: 1721 â 1728.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
apt15413-sup-0001-FigS1.pdf
Size:
81.22KB
Format:
PDF
View/Open
Name:
apt15413.pdf
Size:
550.9KB
Format:
PDF
View/Open
Name:
apt15413_am.pdf
Size:
494.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.